In this week's DermwireTV, new NIH data looks at the association between AD and several health conditions; a study evaluates the effect of lebrikizumab monotherapy in patients with moderate-to-severe AD over 16 weeks; and Andrew Mastro provides tips on how to optimize the first 5 minutes with a patient.
NIH Analysis Examines Association Between AD and Comorbidities
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
In this week's DermwireTV, new NIH data looks at the association between AD and several health conditions; a study evaluates the effect of lebrikizumab monotherapy in patients with moderate-to-severe AD over 16 weeks; and Andrew Mastro provides tips on how to optimize the first 5 minutes with a patient.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Practical Dermatology: Atopic Dermatitis
Understanding Disparities in AD
<p>Understanding Disparities in AD</p>
Practical Dermatology: Atopic Dermatitis
DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
<p>DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab</p>
Practical Dermatology: Atopic Dermatitis
New Drugs Helping AD Catch Up to Psoriasis
<p>New Drugs Helping AD Catch Up to Psoriasis</p>
Practical Dermatology: Atopic Dermatitis
Addressing the Unique Challenges of AD Patients
<p>Addressing the Unique Challenges of AD Patients </p>
Practical Dermatology: Atopic Dermatitis
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
<p>FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?